T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Singh, Nathan ^a   Kulikovskaya, Irina ^b   Barrett, David M ^c   Binder Scholl, Gwendolyn ^d   Jakobsen, Bent ^d   Martinez, Daniel ^c   Pawel, Bruce ^c   June, Carl H ^b   Kalos, Michael D ^e   Grupp, Stephan A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d Adaptimmune Ltd   (United Kingdom)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Cell therapy; Immunotherapy; Neuroblastoma; NY ESO 1; Transgenic TCR

Indexed keywords

ALPHA4 INTEGRIN; CD3 ANTIGEN; HLA A2 ANTIGEN; LENTIVIRUS VECTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; NY ESO 1 ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CELL ENGINEERING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENETIC ENGINEERING; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SHORT TANDEM REPEAT; T LYMPHOCYTE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84954411605     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1040216     Document Type: Article

References (53)

1. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366:2008-16; PMID:22621628; http://dx. doi. org/ 10. 1056/NEJMct1114348
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx. doi. org/10. 1056/ NEJMoa1103849
3. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94:1914-8; PMID:9050879; http://dx. doi. org/10. 1073/pnas. 94. 5. 1914
4. Chen YT, Gure AO, Tsang S, Stockert E, JägerE, KnuthA, OldLJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 1998; 95:6919-23; PMID:9618514; http://dx. doi. org/10. 1073/pnas. 95. 12. 6919
5. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188:22-32; PMID:12445278; http://dx. doi. org/ 10. 1034/j. 1600-065X. 2002. 18803. x
6. Jager E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, et al. Induction of primary NYESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000; 97:12198-203; PMID:11027314; http://dx. doi. org/10. 1073/pnas. 220413497
7. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333-47; PMID:24274181; http://dx. doi. org/10. 1146/annurev-med-060512-150254
8. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx. doi. org/10. 1056/NEJMoa1407222
9. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx. doi. org/ 10. 1056/NEJMoa1215134
10. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx. doi. org/ 10. 1126/scitranslmed. 3002842
11. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx. doi. org/10. 1126/scitranslmed. 3005930
12. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0170
13. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118:6050-6; PMID:21984804; http://dx. doi. org/10. 1182/blood-2011-05-354449
14. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx. doi. org/10. 1038/nm. 1882
15. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigenspecific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174:4415-23; PMID:15778407; http://dx. doi. org/ 10. 4049/jimmunol. 174. 7. 4415
16. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1. J Clin Oncol 2011; 29:917-24; PMID:21282551; http://dx. doi. org/10. 1200/JCO. 2010. 32. 2537
17. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20; PMID:17586306; http://dx. doi. org/10. 1016/S0140-6736(07)60983-0
18. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165-73; PMID:10519894; http://dx. doi. org/10. 1056/NEJM199910143411601
19. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http:// dx. doi. org/10. 1056/NEJMoa0911123
20. Barrett DM, Singh N, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 2014; 16:619-30; PMID:24439255; http://dx. doi. org/10. 1016/j. jcyt. 2013. 10. 013
21. Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jäger E, Cameron BJ, Lissin N, et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 2006; 176:7308-16; PMID:16751374; http://dx. doi. org/10. 4049/jimmunol. 176. 12. 7308
22. Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, Grupp SA, Reid GS. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 2011; 118:e112-7; PMID:21856863; http://dx. doi. org/ 10. 1182/blood-2011-04-346528
23. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 22:1575-86; PMID:21838572; http://dx. doi. org/10. 1089/hum. 2011. 070
24. Burkett MW, Shafer-Weaver KA, Strobl S, Baseler M, Malyguine A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J Immunother 2005; 28:396-402; PMID:16000959; http://dx. doi. org/ 10. 1097/01. cji. 0000165357. 11548. 6d
25. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2014; 2:1059-70; PMID:25104548; http://dx. doi. org/10. 1158/2326-6066. CIR-14-0051
26. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx. doi. org/10. 1126/science. 1251102
27. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121:5154-7; PMID:23678006; http://dx. doi. org/10. 1182/ blood-2013-02-485623
28. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-33; PMID:22592608; http://dx. doi. org/10. 1182/blood-2012-01-400515
29. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25; PMID:24553386; http:// dx. doi. org/10. 1126/scitranslmed. 3008226
30. Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 2013; 20:386-95; PMID:22739387; http://dx. doi. org/10. 1038/gt. 2012. 48
31. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010; 28:2625-34; PMID:20404250; http://dx. doi. org/10. 1200/JCO. 2009. 27. 0421
32. Aung PP, Liu YC, Ballester LY, Robbins PF, Rosenberg SA, Lee CC. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol 2014; 45(2):259-67
33. HeldG, MatsuoM, EpelM, Gnjatic S, Ritter G, Lee SY, Tai TY, CohenCJ, Old LJ, Pfreundschuh M, et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 2004; 34:2919-29; PMID:15368308; http://dx. doi. org/10. 1002/eji. 200425297
34. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-Reactive T-cell receptor: Long-term follow-up and correlates with response. Clin Cancer Res 2015;21:1019-27; PMID:25538264; http:// dx. doi. org/10. 1158/1078-0432. CCR-14-2708
35. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195:346-55; PMID:12704644; http://dx. doi. org/10. 1002/jcp. 10290
36. Klippel ZK, Chou J, Towlerton AM, Voong LN, Robbins P, Bensinger WI, Warren EH. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 2014; 21:337-42; PMID:24451117; http://dx. doi. org/10. 1038/gt. 2013. 87
37. Merchant M, Cristea M, Stadtmauer E, Tap W, D'Angelo S, Grupp SA, Holdich T, Binder-Scholl G, Jakobsen B, Odunsi K, et al. Genetically engineered NY-ESO-1 Specific T cells in HLAA201+ Patients with Advanced Cancers. In: ASCO 2015 Annual Meeting 2015. J Clin Oncol 33, 2015 (suppl; abstr TPS3102)
38. Singh N, Barrett DM, Grupp SA. Roadblocks to success for RNA CARs in solid tumors. OncoImmunology 2015; 3(12):e962974; PMID:25964863
39. Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, Wexler LH, Thiele CJ, Tsokos M, Pinkus JL, Pinkus GS, et al. Interferon-gammadependent infiltration of human T cells into neuroblastoma tumors in vivo. Clin Cancer Res 2009; 15:6602-8; PMID:19825945; http://dx. doi. org/10. 1158/1078-0432. CCR-09-0829
40. Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 2003; 63:1122-9; PMID:12615731
41. Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 1986; 47:667-74; PMID:3096575; http://dx. doi. org/10. 1016/ 0092-8674(86)90509-X
42. Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother 2011; 60:1299-307; PMID:21626030; http://dx. doi. org/10. 1007/ s00262-011-1037-z
43. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx. doi. org/10. 1056/ NEJMoa1200694
44. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx. doi. org/ 10. 1056/NEJMoa1003466
45. John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19:5636-46; PMID:23873688; http://dx. doi. org/10. 1158/1078-0432. CCR-13-0458
46. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18:666-8; PMID:20357779; http://dx. doi. org/ 10. 1038/mt. 2010. 31
47. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx. doi. org/10. 1038/mt. 2010. 24
48. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31; PMID:24777247; http://dx. doi. org/10. 1158/ 2326-6066. CIR-13-0006
49. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 2003; 171:166-74; PMID:12816995; http://dx. doi. org/10. 4049/ jimmunol. 171. 1. 166
50. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17:1453-64; PMID:19384291; http://dx. doi. org/ 10. 1038/mt. 2009. 83
51. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/ refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003; 102:2004-13; PMID:12763934; http://dx. doi. org/10. 1182/blood-2003-01-0095
52. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006; 103:17372-7; PMID:17090675; http://dx. doi. org/10. 1073/pnas. 0608138103
53. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001; 98:8012-7; PMID:11416159; http://dx. doi. org/10. 1073/pnas. 121616198